Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Disc Medicine Fiscal Q4 2021 Earnings Report | CapyFin

Disc Medicine

IRON · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q4 2025 +1.30%Q3 2025 -1.58%Q2 2025 -3.37%Q1 2025 +2.28%Q4 2024 +0.07%Q3 2024 -5.27%Q2 2024 +4.41%Q1 2024 +3.48%Q4 2023 -8.72%Q3 2023 +1.72%Q2 2023 +0.31%Q1 2023 +0.57%Q4 2022 -0.63%Q3 2022 -0.59%Q2 2022 -12.44%Q1 2022 +3.60%Q4 2021 -3.23%Q3 2021 +14.62%Q2 2021 +0.25%

Mar 10, 2022

•

Dec 31, 2021

Disc Medicine Q4 2021 Earnings Report

Reported financial results for the year ended December 31, 2021.

Key Takeaways

Gemini Therapeutics reported its full year 2021 financial results, revealing a net loss of $71.9 million. The company is currently evaluating strategic options to maximize shareholder value.

Gemini Therapeutics is evaluating strategic options.

Net loss for the full year 2021 was $71.9 million.

Research and development expenses were $48.7 million for the full year 2021.

Cash and cash equivalents totaled $136.6 million as of December 31, 2021.